Ominous Death Cross Forms On Alibaba Group Holding’s Chart

If history is any guide, there may be trouble ahead for shares of Alibaba Group Holding (NYSE:BABA). A…

If history is any guide, there may be trouble ahead for shares of Alibaba Group Holding (NYSE:BABA). A so-called “death cross” has formed on its chart and, not surprisingly, this could be bearish for the stock.

What To Know: Many traders use moving average crossover systems to make their decisions.

When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term average price, it means the trend is lower.

Why It’s Important: The 50-day and the 200-day simple moving averages are commonly used.

The death cross occurs when the 50-day moves below the 200-day. This could mean the long-term trend is changing.

That just happened with Alibaba Group Holding, which is trading around $81.44 at publication time.

signals

Remember: Seasoned investors don’t blindly trade Death Crosses.

Instead, they use it as a signal to start looking for short positions based on other factors, like price levels and company fundamentals & events.

For seasoned investors, this is just a sign that it might be time to start considering possible short positions.

With that in mind, take a look at Alibaba Group Holding’s past and upcoming earnings expectations:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 2.37 1.64 1.52 1.10
EPS Actual 2.79 1.82 1.75 1.25
Revenue Estimate 35.76B 29.45B 30.05B 29.94B
Revenue Actual 35.92B 29.12B 30.69B 32.19B

Also consider this overview of Alibaba Group Holding analyst ratings:

ratings

Do you use the Death Cross signal in your trading or investing? Share this article with a friend if you found it helpful!

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Treating PTSD Topically & Directly To The Brain? Psychedelics Delivery Company Poised For Major Breakthrough

Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs directly to the brain, avoiding the traditional “high” and side effects.

BWVI

Read More

Newly Listed Lenz Therapeutics’ Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study

LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary endpoints without compromising distance visual acuity. LNZ100's safety profile remains favorable, paving the way for its lead candidacy, poised for mid-2024 NDA submission.

LENZ